Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Met primary and Hepatic Encephalopathy endpoints in Phase 2 studyIncrease in Skeletal Muscle Index observed at Week 24 was maintained through 52 weeksParticipants on placebo increased SMI when...

Related Keywords

United States ,Arunj Sanyal ,Mahesh Patel ,Jennifer Lai ,Prnewswire Lipocine Inc ,Stravitz Sanyal Institute For Liver Disease Metabolic Health ,Lipocine Inc ,Nasdaq ,Virginia Commonwealth University ,Skeletal Muscle Index ,Overt Hepatic ,For Placebo ,During Stage ,Through Week ,Placebo Converted ,Stravitz Sanyal Institute ,Liver Disease ,Metabolic Health ,End Stage Liver Disease ,Private Securities Litigation Reform Act ,Markets ,